A Polish medical university is offering innovative pharmaceutical composition for the treatment of androgenetic alopecia and/or acne vulgaris under license agreement

Summary

A leading Polish medical university has developed an innovative medicinal product, based on roxithromycinfor, that can be used for treatment of acne vulgaris and androgenetic alopecia. It is now looking for foreign licensees that are willing to obtain IP rights to this formula and introduce it to the market.

Partner sought

Most suitable partners would be companies from Life Science sector with experience in carrying research and development works as well as in implementation of medicinal products on local and international markets. The partner would be granted a license and would be responsible for introducing the drug into the market and for all the marketing activities.

Description

A leading Polish medical university has designed a pharmaceutical composition containing roxithromycinfor to be used as a medicinal product for the treatment of androgenetic alopecia and/or acne vulgaris. Treatment of acne vulgaris and androgenetic alopecia is a difficult and long-lasting process. In the treatment of androgenogenic alopecia, the only approved formulation for topical use by the Food and Drug Administration is 2% and 5% Minoxidil. On the other hand, this substance is suitable for oral therapy, but it is associated with serious side effects and only men can be treated with it. There are no alternative pharmacological agents typically applied in the therapy for alopecia. Acne vulgaris is one of the most common dermatoses and despite the fact that many pharmaceuticals are available in the pharmaceutical market to combat it, more effective and innovative solutions are still sought after. Roxithromycin is an antibiotic from the group of semi-synthetic macrolides. It is a 10-oxy-ether derivative of erythromycin with increased acid resistance and better pharmacokinetic parameters. It is a lipid type of compound. It is used orally in the treatment of Gram-positive infections, less often Gramnegative infections. Its mechanism of action consists of blocking the biosynthesis of bacterial proteins. In addition to the typically antimicrobial activity, roxithromycin also inhibits the production of proinflammatory compounds by bacteria that contribute to the development of acne. There have also been reports of roxithromycin inhibition of free radical formation in neutrophils and inhibition of keratinocyte apoptosis. An innovative pharmaceutical composition containing roxithromycin has been developed which can be used for example for the treatment of androgenetic alopecia and/or acne vulgaris. In order to produce the proposed preparation, lipid micro- and nanoparticles were used as carriers of roxithromycin for hair follicles. The university is offering to sell license/IP rights for the composition of this medicinal product to a foreign partner. The substance must undergo clinical trials in order to be authorised for the market. Potential partner would have to create branding and visual identification of the market-ready product.

Advantages and innovations

Not available

Development stage

Available for demonstration

Intellectual Property Rights (IPR)

Patents granted

Register your interest

How it works

This part is simple. Rather than you going it alone, Innovate UK EDGE are here to help you find the right partner through these live opportunities. This process is just like a professional approach to a business at a networking event.

We use the information you provide below to review and collate the most suitable submissions and share them with our client. To stand the best chance of success, make your submission really sing. Sell why the client who submitted the opportunity should work with you. Excite them. Ask questions. Try and avoid copying and pasting words from elsewhere.

Short description of your organisation, activities, products and services
Short description of your organisation, activities, products and services
What interests you about this opportunity and organisation
 Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
Is there anything further you would like to know about this opportunity
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know
Please verify your identify to continue

Enter your email address and we'll send an email with a 6-digit code to enter below. Then we'll need some further details about you and your company.